Univercells News

Poster and data presented at Vaccine Technology VII conference in Canada demonstrates how its micro-facility can achieve a 10-fold reduction in Polio vaccine manufacturing costs

Brussels, Belgium, July 9, 2018

Univercells recently attended the Vaccine Technology VII conference in Mont-Tremblant, Québec, taking home a first-place prize for its poster (now online) entitled “Disruptive micro-facility for affordable vaccine manufacturing – Case study for sIPV polio vaccine,” presented by its co-founder and CTO, Mr. José Castillo.


In December 2016, Univercells was awarded a $12 million grant by the Bill & Melinda Gates Foundation to develop a breakthrough vaccine manufacturing platform to deliver Sabin inactivated polio vaccine (sIPV) at radically low costs and high capacity, increasing vaccine availability for developing countries.

The two-year development project, including a consortium of Batavia Biosciences and Natrix Separations (Merck KGaA) targets the installation of a first sIPV micro-facility installation delivering 40 million trivalent vaccine doses at a production cost of $0.15 per dose.


Univercells’ poster introduces preliminary data from the ongoing development of its sIPV manufacturing platform, outlining how viral vaccines such as polio can be produced in a fully-contained isolator for increased safety, leading to a tremendous impact on factory design, CAPEX and manufacturing costs.

  • Poster
    | Nevoline, vaccines

    Disruptive micro-facility for affordable vaccine manufacturing

    Discover case study for sIPV polio vaccine